B型主动脉壁内血肿药物治疗失败率高
本研究回顾性分析2008年至2017年单中心92例B型主动脉壁内血肿患者,其中67例初始接受最佳药物治疗。结果显示仅28.4%患者药物治疗成功,20.9%因晚期失败接受腔内治疗,入院时IMH厚度是药物治疗失败的独立预测因素。
要点
- B型主动脉壁内血肿最佳药物治疗失败率高,需密切监测。
- 入院时IMH厚度是预测药物治疗失败的最可靠因素。
- IMH厚度≥8.0 mm时药物治疗失败风险显著增加。
核心结论
- B型主动脉壁内血肿最佳药物治疗失败率高且需要干预。
- 入院时IMH厚度是预测药物治疗失败的最可靠因素。
研究设计与样本
- 单中心回顾性病历审查,纳入2008年1月至2017年12月所有B型主动脉壁内血肿患者。
- 共识别92例患者,其中25例接受急诊胸主动脉腔内修复术,67例初始接受最佳药物治疗。
主要发现
- 67例初始药物治疗患者中,32例因早期失败在14天内接受胸主动脉腔内修复术。
- 另2例早期失败:1例死于逆行A型夹层导致的主动脉破裂,1例建议手术但未遵从并失访。
- 14例(20.9%)在初始住院后因晚期失败接受血管内治疗。
- 药物治疗成功19例(28.4%),其中5例主动脉扩大但低于择期修复阈值(最大主动脉直径55 mm)。
- 单因素分析显示入院时IMH厚度和IMH厚度增长是药物治疗失败的危险因素。
关键数值与推荐
- 药物治疗失败定义为以下任一终点:主动脉破裂、主动脉相关死亡、主动脉扩大至至少55 mm或12个月内增长>10 mm、或因药物治疗失败需行主动脉外科干预。
- 入院IMH厚度预测药物治疗失败的cutoff值为≥8.0 mm。
临床怎么用
- 对B型主动脉壁内血肿患者,应密切监测药物治疗反应,尤其注意入院时IMH厚度。
- 入院IMH厚度≥8.0 mm提示药物治疗失败风险高,应考虑早期干预或更严密随访。
局限性
- 单中心回顾性研究,样本量有限。
- 部分患者失访,可能影响结果完整性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Intramural hematoma (IMH) is on the spectrum of acute aortic syndrome, but optimal management is poorly understood. The aim of this study was to evaluate outcomes of patients with type B IMH (TBIMH) after best medical therapy (BMT) and to assess for risk factors associated with failure of BMT. METHODS: This is a single-institution retrospective chart review of all patients with TBIMH between January 2008 and December 2017. Failure of BMT was defined as any of the following end points: aortic rupture, aorta-related death, aortic enlargement to at least 55 mm or growth of >10 mm within 12 months, or need for surgical aortic intervention for failed BMT. RESULTS: We identified 92 patients, of whom 25 received emergent thoracic endovascular aortic repair; 67 patients were initially managed with BMT, and of these, 32 underwent thoracic endovascular aortic repair within 14 days for early BMT failure. Two additional patients had early BMT failure; one died of aortic rupture due to retrograde type A dissection, and one patient was advised to undergo repair but did not comply and was lost to follow-up. Fourteen patients (20.9%) received endovascular therapy for late failure of BMT after the initial hospitalization. Medical management was successful in 19 patients (28.4%), although 5 patients had aortic enlargement but below the threshold for elective repair (maximal aortic diameter of 55 mm). On univariate analysis, presenting IMH thickness and growth of IMH thickness were risk factors for BMT failure. On multivariate analysis, presenting IMH thickness was the sole predictive risk factor for medical therapy failure (odds ratio, 1.083; 95% confidence interval, 1.021-1.149; P = .008), with an odds ratio of 6.810 (95% confidence interval, 1.921-24.146; P = .002) with a presenting IMH thickness of ≥8.0 mm, which was the calculated IMH thickness cutoff value with highest sensitivity and specificity to predict failure of BMT (area under the receiver operating characteristic curve = 0.795; P = .001; J = 0.62). CONCLUSIONS: BMT for TBIMH is associated with a high failure rate and need for interventions. IMH thickness on admission is the most reliable factor to predict failure of BMT.
引用
- Mesar T, Lin MJ, Kabir I, et al. Medical therapy in type B aortic intramural hematoma is associated with a high failure rate. J Vasc Surg. 2020. PMID: 32063446. doi:10.1016/j.jvs.2019.07.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。